You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Stage IIIb/ IV NSCLC harbouring HER2 exon 20 mutations

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Worldwide (Afatinib)

Completed
Has Results
  • NSCLC
  • Köln, Germany
  • +4 more
Aug 23, 2022

NSCLC Trial in Winter Haven (Poziotinib, Docetaxel)

Suspended
  • NSCLC
  • Winter Haven, Florida
    Bond Clinic, P.A.
Jan 27, 2023

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

Recruiting
  • EGFR Exon 20 Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

Terminated
  • NSCLC, Stage IV
  • +7 more
  • tarloxotinib bromide
  • Irvine, California
  • +13 more
Nov 11, 2021

Locally Advanced or Metastatic NSCLC Trial in Worldwide (Trastuzumab Deruxtecan, Cisplatin, Carboplatin)

Recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Trastuzumab Deruxtecan
  • +4 more
  • Anchorage, Alaska
  • +148 more
Aug 11, 2022

Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Dublin, Ireland
  • +24 more
Aug 23, 2022

NSCLC Trial in Singapore (Afatinib 40 MG)

Not yet recruiting
  • NSCLC
  • Afatinib 40 MG
  • Singapore, Singapore
    National University Hospital
Sep 25, 2023

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

China With Non-Small-Cell Lung Cancer That is Unable to be

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    May 16, 2023

    NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +14 more
    • Glendale, California
    • +12 more
    Feb 2, 2023

    NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Jul 19, 2022

    Double-dose Furmonertinib in Treatment of Slow

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Oct 31, 2023

    Non Small Cell Lung Cancer Trial in Durham, Columbus, Pittsburgh (osimertinib)

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • Durham, North Carolina
    • +2 more
    Jun 30, 2022

    NSCLC Trial in Worldwide (Poziotinib)

    Active, not recruiting
    • NSCLC
    • Phoenix, Arizona
    • +62 more
    Jan 27, 2023

    Learn About Tests Looking forGene Mutation in Lung Cancer in

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • No Intervention
    • Beijing, China
      Department of Pathology, National Cancer Center/National Clinica
    Feb 24, 2023

    EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)

    Active, not recruiting
    • EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
    • Großhansdorf, Germany
    • +17 more
    Jan 12, 2023

    NSCLC Trial in Worldwide (Nivolumab)

    Completed
    Has Results
    • Non-Small Cell Lung Cancer
    • Wels, Oberösterreich, Austria
    • +89 more
    Oct 17, 2022

    NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +13 more
    • furmonertinib 240 mg
    • +2 more
    • Yuma, Arizona
    • +37 more
    Dec 14, 2022

    NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • MK-2870
    • +2 more
    • (no location specified)
    Oct 3, 2023

    Non-squamous NSCLC Trial (biological, drug, dietary supplement)

    Not yet recruiting
    • Non-squamous NSCLC
    • Pembrolizumab
    • +7 more
    • (no location specified)
    Feb 20, 2023

    Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 Trial in United States

    Recruiting
    • Lung Non-Small Cell Carcinoma
    • +5 more
    • San Francisco, California
    • +3 more
    Aug 17, 2022

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Duarte, California
    • +228 more
    Jan 31, 2023